A Meta-analysis of Cinacalcet in the treatment of dialysis patients with secondary hyperparathyroidism

Objective To evaluate the efficacy and safety of cinacalcet in the treatment of dialysis patients with seondary hyperparathyroidism.Methods Retrieved from Pumed,Embase,Cochrane Library, OVID, CNKI, SinoMed,Wanfang data-base. The limited range was from the establishment of this database to March 2017, Get the randomized controlled trials about cinacalcet in the treatment of dialysis patients with secondary hyperparathyroidism. Data were extractedand evaluated by two reviewers independently, and meta-analysis was performed with RevMan 5.3.5.Results A total of 18 randomized controlled trials involving 8194 patients were included. The meta-analysis showed that compared with conventional therapy,cinacalcet cansignificantly decrese parathyroid hormone in SHPT patients,and decrease the level of FGF23, decrease the level of serum calcium,decrease the level of serum phosphrus, decrease the level of Ca×P, Compared with the control group, the patient of the cinacalcet group was more prone to nausea,vomiting,diarrhea and hypocalcemia, it showed no statistical significance of the difference of all-cause mortality.Conclusions Cinacalcet can effectively reduce the level of PTH,FGF23,calcium,phosphorus and Ca×P in dialysis patients with secondary hyperparathyroidism and can not reduce the risk of all-cause mortality;increase the risk of nausea,vomiting,diarrhea and hypocalcemia.